Medical device company GE HealthCare has announced the integration of its advanced AIR technologies with the SIGNA PET/MR AIR system, which will be unveiled at the 2023 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

The integration is aimed to increase diagnostic precision, streamline evaluation of treatment, and improve the comfort of the patient.

GE HealthCare’s AIR technologies include AIR Coils, which adapt to the shape of the human body to improve both patient comfort and the quality of magnetic resonance (MR) imaging.

The technologies also include AIR Recon DL, which offers deep learning-based MR image reconstruction to enhance MR image quality and lowers scan time by 50%.

Additionally, the technologies includes MotionFree Brain, which lessens motion-related PET image degradation without external tracking devices. This allows clinicians to view clear and still brain images.

Through the integration, the SIGNA PET/MR imaging system can help in confident diagnoses and personalised treatment recommendations in oncology and neurology care areas, including prostate cancer and Alzheimer’s disease, said the company.

The system also combines the anatomical precision of MRI and GE HealthCare’s high-sensitivity PET with prostate-specific membrane antigen (PSMA)-targeted PET radiotracers to diagnose and stage/re-stage prostate cancer precisely.

Furthermore, it can help with the selection of patients for upcoming PSMA-targeted radioligand therapy, the medical device firm said.

According to GE HealthCare, SIGNA PET/MR AIR provides a sensitive Time-of-Flight (ToF) PET detector in a PET/MR for early possible diagnosis, assessment of the disease progression, and detection of adverse effects in a single scan.

GE HealthCare MR president and CEO Jie Xue said: “The SIGNA PET/MR AIR system continues our legacy of delivering innovative technologies that address a comprehensive range of clinical diseases.

“Our latest PET/MR technology will directly impact the most challenging diseases, such as prostate cancer and Alzheimer’s Disease. These diseases require precise and comprehensive imaging for accurate diagnosis, treatment planning, and therapy monitoring.

“We are excited to see SIGNA PET/MR AIR addressing these challenges and fulfilling our vision of providing access to advanced, personalised care.”